Prognostic significance of survivin in breast cancer: Meta-analysis

Breast Journal

Volumn 20, Issue 5, 2014, Pages 514-524

  Li, Yanyan ^a   Ma, Xuelei ^a   Wu, Xi ^a   Liu, Xiaoxiao ^a   Liu, Lei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Breast cancer; Meta analysis; Prognostic factor; Survivin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SURVIVIN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE METASTASIS; MENOPAUSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; PUBLISHING; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SYSTEMATIC REVIEW; TUMOR VOLUME; ADULT; AGED; BREAST TUMOR; FEMALE; HEALTH; META ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLOBAL HEALTH; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908137596     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12303     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Reed JC, Bischoff JR. BIRinging chromosomes through cell division-and survivin' the experience. Cell 2000;102:545-8.
3. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
4. Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol 2011;49:26-33.
5. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115:575-85.
6. Sui L, Dong Y, Ohno M, et al. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 2002;21:315-20.
7. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-4.
8. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000;46:645-50.
9. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452-3.
10. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 2002;184:105-16.
11. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003;9:4914-25.
12. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
13. O'Driscoll L, Linehan R, M Kennedy S, Cronin D, Purcell R, et al. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 2003;201:225-36.
14. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, et al. Prognostic importance of survivin in breast cancer. Br J Cancer 2003;88:1077-83.
15. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004;50:1986-93.
16. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
17. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
18. Williamson PR, Smith CT, Hutton JL, et al. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21:3337-51.
19. Begg CB. Publication bias. Biometrics 1994;299:25.
20. Kleinberg L, Flørenes VA, Nesland JM, Davidson B. Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. Am J Clin Pathol 2007;128:389-97.
21. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006;94:253-8.
22. Dogu GG, Ozkan M, Ozturk F, Dikilitas M, Er O, et al. Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med Oncol 2010;27:34-9.
23. Kostadima L, Pentheroudakis G, Fountzilas G, Dimopoulos M, Pectasides D, et al. Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat 2006;100:161-7.
24. Massidda B, Sini M, Budroni M, Atzori F, Deidda MP, et al. Molecular alterations in key-regulator genes among patients with T4 breast carcinoma. BMC Cancer 2010;10:458.
25. Nassar A, Lawson D, Cotsonis G, Cohen C. Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol 2008;16:113-20.
26. Nassar A, Sexton D, Cotsonis G, Cohen C. Survivin expression in breast carcinoma: correlation with apoptosis and prognosis. Appl Immunohistochem Mol Morphol 2008;16:221-6.
27. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006;17:597-604.
28. Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, et al. Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 2006;60:289-92.
29. Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA, et al. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer. Clin Chem 2006;52:1693-700.
30. Tsai WC, Chu CH, Yu CP, Sheu LF, Chen A, et al. Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 2008;24:89-99.
31. Yakirevich E, Samkari A, Holloway MP, Lu S, Singh K, et al. Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer. Hum Pathol 2012;43: 865-73.
32. Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 2007;27:2803-8.
33. Younis T, Haché KD, Rayson D, Dewar R, Gray S, et al. Survivin and COX-2 expression in male breast carcinoma. Breast 2009;18:228-32.
34. Al-Joudi FS, Iskandar ZA, Imran AK. Survivin expression correlates with unfavourable prognoses in invasive ductal carcinoma of the breast. Med J Malaysia 2007;62:6-8.
35. Son BH, Choi JS, Lee JH. Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast. Pathology 2005;37:131-6.
36. Mao J, Hai J, Shu HP, Wu YH, Ou HY, et al. [Expressions of survivin and nm23 and the relationship among the expressions and the axillary lymph node metastasis in breast cancer]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2005;30:312-4, 334.
37. Zhang SQ, Qiang SY, Yang WB, Jiang JT, Ji ZZ. [Expression of survivin in different stages of carcinogenesis and progression of breast cancer]. Ai Zheng 2004;23:697-700.
38. Qi G, Tuncel H, Aoki E, et al. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep 2009;22:557-62.
39. Ulukus EC, Kargi HA, Sis B, Lebe B, Oztop I, et al. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Appl Immunohistochem Mol Morphol 2007;15:31-7.
40. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-102.
41. Yamada Y, Kuroiwa T, Nakagawa T, et al. Transcriptional expression of Survivin and its splice variants in brain tumors in humans. J Neurosurg 2003;99:738-45.
42. Semba S, Trapasso F, Fabbri M, McCorkell KA,Volinia S, et al. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 2006;25:2860-72.
43. Kesisis G, Kontovinis LF, Gennatas K, Kortsaris AH. Biological markers in breast cancer prognosis and treatment. J BUON 2010;15:447-54.
44. Cheson BD, Bartlett NL, Vose JM, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2011;118:3128-34.
45. Cheng Q, Ling X, Haller A, et al. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 2011;3:179-97.
46. Chen X, Wang T, Yang D, et al. Expression of the IAP protein family acts cooperatively to predict prognosis in human bladder cancer patients. Oncol Lett 2013;5:1278-84.
47. Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug development in oncology. Onco Targets Ther 2013;9:1285-304.
48. Yang D, Song X, Zhang J, et al. Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim Biophys Sin (Shanghai) 2010;42:137-44.
49. Li G, Chang H, Zhai YP, et al. Targeted silencing of inhibitors of apoptosis proteins with siRNAs: a potential anti-cancer strategy for hepatocellular carcinoma. Asian Pac J Cancer Prev 2013; 14:4943-52.